A review of Palantir's data deal with the NHS has been initiated, following claims that NHS England missed an opportunity to support the growth of the UK's health tech sector. The decision to call in the contract for a second opinion suggests that there may be concerns about the terms of the agreement or its alignment with the NHS's goals. The review is likely to involve a closer examination of the deal's potential impact on the UK's health tech industry. The implications of this development are unclear, but it is likely that the review will be closely watched by those interested in the intersection of healthcare and technology.

AI summaries can be wrong sometimes—always verify important details using the source article.